Scholars@Duke

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Tempero, MA; Malafa, MP; Al-Hawary, M; Behrman, SW; Benson, AB; Cardin, DB; Chiorean, EG; Chung, V; Czito, B; Del Chiaro, M; Dillhoff, M ...
Published in: J Natl Compr Canc Netw
April 1, 2021
Published version (DOI) Link to item

Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced and metastatic disease.

Duke Scholars

Brian Gary Czito
Author Brian Gary Czito Radiation Oncology
Jorge Valdemar Obando
Author Jorge Valdemar Obando Medicine, Gastroenterology
Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2021.0017

EISSN

1540-1413

Publication Date

April 1, 2021

Volume

19

Issue

4

Start / End Page

439 / 457

Location

United States

Related Subject Headings

  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Humans
  • Adenocarcinoma
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., … George, G. V. (2021). Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(4), 439–457. https://doi.org/10.6004/jnccn.2021.0017
Tempero, Margaret A., Mokenge P. Malafa, Mahmoud Al-Hawary, Stephen W. Behrman, Al B. Benson, Dana B. Cardin, E Gabriela Chiorean, et al. “Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 19, no. 4 (April 1, 2021): 439–57. https://doi.org/10.6004/jnccn.2021.0017.
Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Apr 1;19(4):439–57.
Tempero, Margaret A., et al. “Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw, vol. 19, no. 4, Apr. 2021, pp. 439–57. Pubmed, doi:10.6004/jnccn.2021.0017.
Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Apr 1;19(4):439–457.

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2021.0017

EISSN

1540-1413

Publication Date

April 1, 2021

Volume

19

Issue

4

Start / End Page

439 / 457

Location

United States

Related Subject Headings

  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Humans
  • Adenocarcinoma
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis